

EDSS: Change from Part 1 baseline to each scheduled efficacy visit in Part 2
Subgroup Analysis: Confirmed Progression of disability
ITT population

Confirmed Progressors

| | Placebo to Natalizumab 300 mg | Natalizumab 300 mg | p-value (a) |
|----------------------------------|----------------------------------|-----------------------|-------------|
| Change from Baseline to Week 156 | | | |
| n | 162 | 141 | |
| Mean | 0.38 | 0.36 | 0.7122 |
| SD | 0.631 | 0.703 | |

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (≤ 5.5 or ≥ 6).

EDSS: Change from Part 1 baseline to each scheduled efficacy visit in Part 2
 Subgroup Analysis: Confirmed Progression of disability
 ITT population

Non Progressors

| | Placebo to Natalizumab 300 mg | Natalizumab 300 mg | p-value (a) |
|----------------------------------|----------------------------------|-----------------------|-------------|
| Change from Baseline to Week 156 | | | |
| n | 98 | 134 | |
| Mean | -0.33 | -0.25 | 0.3861 |
| SD | 0.718 | 0.775 | |

(a) p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (≤ 5.5 or ≥ 6).